Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9512172 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4358861 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4351333 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4367331 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL4356731 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL2045162 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL3628921 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Cyclooctene SCHEMBL153391 | 1.00 | — | — | |
| SCHEMBL9514981 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Cyclohexene SCHEMBL21635113 | 1.00 | HDAC3 (0.31) | HDAC3HDAC4HDAC1HDAC7HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113372207-B | Synthesis method of muscone intermediate 2-cyclopentadecanone | 无锡济煜山禾药业股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| CN-111440327-B | Deuterated supramolecular polymer and preparation method thereof | 中国工程物理研究院材料研究所 | 2022-03-29 | — | — | CN | claimed |
| CN-111440327-A | Deuterated supramolecular polymer and preparation method thereof | 中国工程物理研究院材料研究所 | 2020-07-24 | — | — | CN | claimed |
| EP-3365418-A2 | PARTICLES FOR MALODOR REDUCTION | The Procter and Gamble Company (US) | 2018-08-29 | — | — | EP | claimed |
| EP-3197511-A1 | PERSONAL CARE COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-02 | — | — | EP | claimed |
| EP-3197423-A1 | PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-02 | — | — | EP | claimed |
| EP-3197422-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | The Procter & Gamble Company (US) | 2017-08-02 | — | — | EP | claimed |
| EP-3197424-A1 | FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-02 | — | — | EP | claimed |
| EP-3197508-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-02 | — | — | EP | claimed |
| CN-106946679-A | A kind of preparation method of the cyclopentadecylene ketone of E 2 | 苏州碳壹科技有限公司 | 2017-07-14 | — | — | CN | claimed |
| EP-1771492-A1 | STIMULATEABLE POLYMER PARTICLES EXHIBITING REACTIVE FUNCTIONS, METHOD FOR THE PRODUCTION AND THE USE THEREOF | Centre National De La Recherche Scientifique (FR) | 2007-04-11 | — | — | EP | claimed |
| EP-1758621-A1 | BIOACTIVE BIOMATERIALS FOR CONTROLLED DELIVERY OF ACTIVE PRINCIPLES | The Centre National de la Recherche Scientifique (FR) | 2007-03-07 | — | — | EP | claimed |
| US-7145041-B2 | Method for producing saturated alcohols, ketones, aldehydes and carboxylic acids | DEGUSSA AG (DE) | 2006-12-05 | — | — | US | claimed |
| EP-1401797-B1 | METHOD FOR PRODUCING SATURATED ALCOHOLS, KETONES, ALDEHYDES AND CARBOXYLIC ACIDS | DEGUSSA (DE) | 2006-08-09 | — | — | EP | claimed |
| WO-2006008387-A1 | STIMULATEABLE POLYMER PARTICLES EXHIBITING REACTIVE FUNCTIONS, METHOD FOR THE PRODUCTION AND THE USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-01-26 | — | — | WO | claimed |
| WO-2006008386-A1 | BIOACTIVE BIOMATERIALS FOR CONTROLLED DELIVERY OF ACTIVE PRINCIPLES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2006-01-26 | — | — | WO | claimed |
| US-6852893-B2 | Method for oxidizing hydrocarbons | CREAVIS GESELLSCHAFT FUER TECHNOLOGIE AND INNOVATION MBH (DE) | 2005-02-08 | — | — | US | claimed |
| US-20040249197-A1 | Method for producing saturated alcohols, ketones, aldehydes and carboxylic acids | DEGUSSA AG (DE) | 2004-12-09 | — | — | US | claimed |
| EP-1268367-B1 | METHOD FOR OXIDIZING HYDROCARBONS | DEGUSSA (DE) | 2004-07-21 | — | — | EP | claimed |
| US-20030176733-A1 | Method for oxidizing hydrocarbons | CREAVIS GESELLSCHAFT FUER TECHNOLOGIE UND INNOVATION MBH (DE) | 2003-09-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176733-A1 | Method for oxidizing hydrocarbons | CBR1, CBR3, SCO2 | HDAC3 2081/4885HDAC4 3853/4885HDAC1 2170/4885 |
| US-20040249197-A1 | Method for producing saturated alcohols, ketones, aldehydes and carboxylic acids | CBR1, CYP2E1, AOX1 | HDAC3 1785/4885HDAC4 2799/4885HDAC1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.